Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)

NCT03627091 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
40
Enrollment
INDUSTRY
Sponsor class

Stopped Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.

Conditions

Interventions

Sponsor

Shire